Shilpa Medicare Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Shilpa Medicare's Novel Complex Injectable OERIS (Ondansetron Extended-Release Injection, 100 mg/mL) receives final approval from Subject Expert Committee (SEC) for grant of marketing authorization.".
Shilpa Medicare Limited Press Release Sep 11 2026
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Shilpa Medicare Limited has received final approval from the Subject Expert Committee for marketing authorization of OERIS™, an extended-release injectable formulation of ondansetron. This approval is significant as OERIS™ is designed to provide sustained antiemetic action for an extended period following a single administration, marking a first in both India and globally. The approval follows successful completion of a Phase III trial evaluating the safety and efficacy of OERIS™ for managing chemotherapy-induced nausea and vomiting. Shilpa plans to launch OERIS™ commercially across India following this authorization.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Shilpa Medicare Limited on 6ix
Earlier from Shilpa Medicare
- Shilpa Medicare Limited Press Release Jun 30 2026
- Shilpa Medicare Limited Press Release Jun 24 2026
- Press Release Jun 03 2026
- SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
- Press Release Feb 24 2026
Follow Shilpa Medicare into a list and get an email when it puts out news.
Follow Shilpa Medicare